Heather A. Wakelee

33.1k total citations · 4 hit papers
447 papers, 13.5k citations indexed

About

Heather A. Wakelee is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Heather A. Wakelee has authored 447 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 327 papers in Pulmonary and Respiratory Medicine, 285 papers in Oncology and 76 papers in Cancer Research. Recurrent topics in Heather A. Wakelee's work include Lung Cancer Treatments and Mutations (278 papers), Lung Cancer Diagnosis and Treatment (127 papers) and Lung Cancer Research Studies (97 papers). Heather A. Wakelee is often cited by papers focused on Lung Cancer Treatments and Mutations (278 papers), Lung Cancer Diagnosis and Treatment (127 papers) and Lung Cancer Research Studies (97 papers). Heather A. Wakelee collaborates with scholars based in United States, Canada and France. Heather A. Wakelee's co-authors include Joel W. Neal, Billy W. Loo, Maximilian Diehn, Joseph B. Shrager, Sukhmani K. Padda, Aaron M. Newman, Ash A. Alizadeh, Chih Long Liu, Scott V. Bratman and Robert E. Merritt and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Heather A. Wakelee

421 papers receiving 13.3k citations

Hit Papers

An ultrasensitive method ... 2011 2026 2016 2021 2014 2016 2023 2011 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
    2014 1.5k citations Aaron M. Newman, Joel W. Neal et al. profile →
  2. Integrated digital error suppression for improved detection of circulating tumor DNA
    2016 716 citations Aaron M. Newman, Jacob J. Chabon et al. profile →
  3. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
    2023 460 citations Heather A. Wakelee, Moïshe Liberman et al. profile →
  4. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
    2011 399 citations Heather A. Wakelee et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Heather A. Wakelee 7.5k 6.9k 4.0k 3.9k 1.2k 447 13.5k
Jin Seok Ahn 7.8k 1.0× 8.6k 1.3× 3.0k 0.8× 3.2k 0.8× 1.1k 0.9× 452 13.5k
Beow Y. Yeap 10.3k 1.4× 7.1k 1.0× 2.2k 0.5× 3.1k 0.8× 1.1k 0.9× 206 14.4k
David Planchard 10.0k 1.3× 11.0k 1.6× 3.4k 0.9× 4.6k 1.2× 1.3k 1.1× 431 16.5k
Stefan Sleijfer 4.7k 0.6× 7.1k 1.0× 3.5k 0.9× 4.2k 1.1× 1.3k 1.0× 379 13.6k
Hedy L. Kindler 7.3k 1.0× 8.4k 1.2× 3.1k 0.8× 3.6k 0.9× 860 0.7× 400 16.1k
Vivek Subbiah 4.6k 0.6× 6.0k 0.9× 3.1k 0.8× 3.7k 0.9× 1.7k 1.4× 599 12.2k
Sabino De Placido 4.5k 0.6× 7.8k 1.1× 3.7k 0.9× 4.4k 1.1× 1.0k 0.8× 381 14.0k
Keyue Ding 8.4k 1.1× 8.1k 1.2× 2.6k 0.7× 3.4k 0.9× 1.0k 0.9× 218 14.5k
Primo N. Lara 8.5k 1.1× 7.0k 1.0× 3.5k 0.9× 6.0k 1.5× 637 0.5× 458 16.3k
George R. Blumenschein 5.1k 0.7× 7.0k 1.0× 2.4k 0.6× 2.7k 0.7× 1.4k 1.1× 328 12.0k

Countries citing papers authored by Heather A. Wakelee

Since Specialization
Citations

This map shows the geographic impact of Heather A. Wakelee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather A. Wakelee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather A. Wakelee more than expected).

Fields of papers citing papers by Heather A. Wakelee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather A. Wakelee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather A. Wakelee. The network helps show where Heather A. Wakelee may publish in the future.

Co-authorship network of co-authors of Heather A. Wakelee

This figure shows the co-authorship network connecting the top 25 collaborators of Heather A. Wakelee. A scholar is included among the top collaborators of Heather A. Wakelee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather A. Wakelee. Heather A. Wakelee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Choi, Eunji, Julie Wu, Joel W. Neal, et al.. (2024). Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study. Clinical Lung Cancer. 25(8). 705–711.e7. 1 indexed citations
2.
Planck, Maria, et al.. (2024). Intrathecal pemetrexed for leptomeningeal metastases in a patient with ALK-rearranged lung adenocarcinoma: a case report. Cancer Chemotherapy and Pharmacology. 95(1). 6–6.
3.
Aredo, Jacqueline V., Heather A. Wakelee, Kavitha Ramchandran, et al.. (2024). Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC. JTO Clinical and Research Reports. 5(12). 100741–100741. 1 indexed citations
4.
Garassino, Marina Chiara, Heather A. Wakelee, Jonathan Spicer, et al.. (2024). Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8012–8012. 2 indexed citations
5.
6.
7.
Wakelee, Heather A., Moïshe Liberman, Terufumi Kato, et al.. (2023). KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.. Journal of Clinical Oncology. 41(17_suppl). LBA100–LBA100. 11 indexed citations
8.
Hui, Caressa, Eleanor Brown, Millie Das, et al.. (2023). Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer. 25(2). 186–189. 1 indexed citations
9.
Adderley, Helen, J. Searle, L Wilson, et al.. (2023). 2253P RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer. Annals of Oncology. 34. S1159–S1160.
10.
Patel, Sandip Pravin, Nathaniel J. Myall, Amit Kulkarni, et al.. (2022). Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment. JCO Precision Oncology. 6(6). e2100551–e2100551. 4 indexed citations
11.
Aredo, Jacqueline V., Natasha Purington, Li Su, et al.. (2021). Metabolomic profiling for second primary lung cancer: A pilot case-control study. Lung Cancer. 155. 61–67. 11 indexed citations
12.
Hellyer, Jessica A., Rebecca M. Gardner, Kristen Cunanan, et al.. (2021). Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer. 23(3). 264–272. 17 indexed citations
13.
Jeong, Youngtae, Jessica A. Hellyer, Henning Stehr, et al.. (2019). Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(1). 274–281. 80 indexed citations
14.
Horn, Leora, Jeffrey R. Infante, Karen L. Reckamp, et al.. (2018). Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clinical Cancer Research. 24(12). 2771–2779. 131 indexed citations
15.
Nagpal, Seema, et al.. (2018). Osimertinib for EGFR -Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. The Oncologist. 24(6). 836–843. 35 indexed citations
16.
Varlotto, John M., John C. Flíckinger, Malcolm M. DeCamp, et al.. (2018). Population‐based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. Cancer Medicine. 7(4). 1211–1220. 23 indexed citations
17.
Chaudhuri, Aadel A., Alex Lovejoy, Jacob J. Chabon, et al.. (2016). CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 96(2). S41–S42. 3 indexed citations
18.
Gomez, Scarlett Lin, Juan Yang, Shih‐Wen Lin, et al.. (2015). Incidence Trends of Lung Cancer by Immigration Status among Chinese Americans. Cancer Epidemiology Biomarkers & Prevention. 24(8). 1157–1164. 12 indexed citations
19.
Gubens, Matthew A. & Heather A. Wakelee. (2010). Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis. Dove Medical Press (Taylor and Francis Group). 2 indexed citations
20.
Wakelee, Heather A., Ellen T. Chang, Scarlett Lin Gomez, et al.. (2007). Lung Cancer Incidence in Never Smokers. Journal of Clinical Oncology. 25(5). 472–478. 435 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jin Seok Ahn Breakdown of academic impact, for papers by Beow Y. Yeap Breakdown of academic impact, for papers by David Planchard Breakdown of academic impact, for papers by Stefan Sleijfer Breakdown of academic impact, for papers by Hedy L. Kindler Breakdown of academic impact, for papers by Vivek Subbiah Breakdown of academic impact, for papers by Sabino De Placido Breakdown of academic impact, for papers by Keyue Ding Breakdown of academic impact, for papers by Primo N. Lara Breakdown of academic impact, for papers by George R. Blumenschein
Rankless by CCL
2026